SynthesisDermatology and therapy2026
Risk of Cancer in Patients with Hidradenitis Suppurativa: A Systematic Review and Meta-analysis.
Synthesis in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease. Emerging evidence suggests that the chronic systemic inflammation may predispose patients to an increased risk of malignancy. Despite this, information on cancer occurrence in patients with HS is scarce, and no meta-analysis has explored which types of cancer are more prevalent in patients with HS.
methodsPubMed, Embase, and Web of Science were searched from inception until 7 March 2025 for studies investigating the risk of cancer in patients with HS compared with the general population. In addition, authors of unpublished studies (e.g., conference abstracts) were contacted for data retrieval. Studies had to report the number and/or risk of cancer overall or subtypes of cancer in patients with HS compared with the general population. Two independent authors conducted the screening and extracted data. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. An inverse-variance-weighted random-effects meta-analysis was performed to calculate pooled odds ratio (ORs) and corresponding 95% confidence interval (CIs). The prespecified primary outcome was the risk of cancer overall and subtypes of cancer in patients with HS compared with the general population.
resultsA total of 11 studies encompassing 624,721 patients with HS and 393,691,636 controls were included. Compared with controls, patients with HS had a significantly elevated risk of cancer overall (OR: 1.82; 95% CI 1.13-2.93; p = 0.018) and of gastrointestinal (OR: 1.61; 95% CI 1.29-2.01; p = 0.0002), head and neck (OR: 2.41; 95% CI 1.92-3.02; p = 0.00005), hematological (OR: 1.71; 95% CI 1.38-2.12; p = 0.00005), respiratory cancers (OR: 1.81; 95% CI 1.03-3.17; p = 0.04), Hodgkin lymphoma (OR: 2.44; 95% CI 1.55-3.85; p = 0.0001), and non-Hodgkin lymphoma (OR: 1.15; 95% CI 1.03-1.29; p = 0.01). Few studies reported estimates adjusted for ethnicity and environmental risk factors.
conclusionsHaving HS was associated with an increased risk of cancer overall, including several specific subtypes. Studies adjusting for confounders are highly warranted to assess the long-term association between HS and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.